N-methyl amisulpride - LB pharmaceuticals
Alternative Names: LB 102; LB 102 LAI; LB-102 - LB PharmaceuticalsLatest Information Update: 14 Apr 2025
At a glance
- Originator LB Pharmaceuticals
- Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Schizophrenia
Most Recent Events
- 31 Mar 2025 Updated efficacy and adverse events data from the phase II NOVA trial in Schizophrenia released by LB Pharmaceuticals
- 31 Mar 2025 LB Pharmaceuticals plans a phase III trial for Schizophrenia in the fourth quarter of 2025
- 11 Feb 2025 LB Pharmaceuticals plans a phase III trial for Schizophrenia and additional Neuropsychiatric indications